On 25 January, IFPMA delivered a statement on health emergencies at the WHO 154th Executive Board in Geneva, Switzerland.
Read moreOn 24 January, IFPMA, GSCF, and IGBA delivered a joint constituency statement on non-communicable diseases and Universal Health Coverage (UHC) at the WHO 154th Executive Board in Geneva, Switzerland.
Read moreEncouraging clinical research in low-income settings is essential to tap into opportunities that can make a difference in patients’ lives. Sarah Adam, Associate Director, Regulatory Affairs at IFPMA, shares perspectives on key pillars to support this.
Read more
In September, some 200 Heads of State and top political decision-makers met in New York for the annual United Nations General Assembly. They recommitted to the UN Sustainable Development Goals (SDGs), with a political declaration pledging to “act with urgency to realize the [Agenda 2030] vision.” Halfway to 2030 and with the clock ticking, the renewal...
Read more
On 7 December, IFPMA submitted a statement to the 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005), happening in Geneva, Switzerland.
Read moreIn view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read more
On 3 December, innovative pharmaceutical trade associations issued a joint statement on the Declaration on Climate and Health at COP28.
Read moreThe Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York on 28 November 2023, to discuss global health challenges and public health policies impacting biomedical innovation. 1 December 2023, New York City – The CEOs of leading biopharmaceutical companies met to focus on global health challenges and the importance...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have today announced a new three-year phase of their partnership, aiming to boost the skills and capacity needed to drive increased research and development of new medicines in Africa.
Read more
To mark World Antimicrobial Awareness Week (WAAW) 2023, the International Alliance of Patients’ Organizations (IAPO), the IAPO Patients for Patient Safety Observatory and its AMR Patient Alliance, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the World Medical Association (WMA), the International Council of Nurses (ICN) and International Pharmaceutical Federation (FIP), call for cross-sectoral collaboration to address the growing threat of AMR.
Read moreThis study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States). In a forthcoming publication, OHE will...
Read more
IFPMA’s Thomas Cueni to retire in April 2024, with Dr. David Reddy succeeding him as Director General
Read more